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Abstract
Cancer cells predominantly utilize glycolysis for ATP production even in the presence of abundant oxygen, an environment
that would normally result in energy production through oxidative phosphorylation. Although the molecular mechanism for
this metabolic switch to aerobic glycolysis has not been fully elucidated, it is likely that mitochondrial damage to the
electron transport chain and the resulting increased production of reactive oxygen species are significant driving forces. In
this study, we have investigated the role of the transcription factor Ets-1 in the regulation of mitochondrial function and
metabolism. Ets-1 was over-expressed using a stably-incorporated tetracycline-inducible expression vector in the ovarian
cancer cell line 2008, which does not express detectable basal levels of Ets-1 protein. Microarray analysis of the effects of Ets-
1 over-expression in these ovarian cancer cells shows that Ets-1 up-regulates key enzymes involved in glycolysis and
associated feeder pathways, fatty acid metabolism, and antioxidant defense. In contrast, Ets-1 down-regulates genes
involved in the citric acid cycle, electron transport chain, and mitochondrial proteins. At the functional level, we have found
that Ets-1 expression is directly correlated with cellular oxygen consumption whereby increased expression causes
decreased oxygen consumption. Ets-1 over-expression also caused increased sensitivity to glycolytic inhibitors, as well as
growth inhibition in a glucose-depleted culture environment. Collectively our findings demonstrate that Ets-1 is involved in
the regulation of cellular metabolism and response to oxidative stress in ovarian cancer cells.
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Introduction
Over 50 years ago, Otto Warburg first proposed that
mitochondrial injury that leads to depressed electron transport
chain function and respiratory defects is an important step in the
development and progression of carcinogenesis [1,2]. Over the past
two decades, many studies have shown that tumours preferentially
use glycolysis for energy production over oxidative phosphorylation,
a characteristic that has become a hallmark of tumour pathophys-
iology [3–5]. Known as the Warburg effect, cancer cells pre-
dominantly utilize glycolysis for ATP production even in the
presence of abundant oxygen, an environment that would normally
result in energy production through oxidative phosphorylation
[2,6]. Alterations in mitochondrial DNA correspond to increased
production of ROS and impaired oxidative phosphorylation,
resulting in decreased ATP production and increased glycolytic
dependence [5,7]. The increased production of reactive oxygen
species, particularly H2O2, by cancer cells is likely the result of
mitochondrial dysfunction, as mitochondria are considered to be
the predominant cellular source of reactive oxygen species [8]. Four
to five percent of the O2 consumed by oxidative phosphorylation in
the mitochondria is normally converted to reactive oxygen species;
therefore defects to the electron transport chain system in cancer
cells would result in excessive reactive oxygen species formation
[8–10]. Excessively produced, H2O2 can act as a signaling molecule
by oxidizing cysteine molecules on proteins, activating several
signalingpathways includingMAPK, aswell asseveraltranscription
factors including AP-1, p53, NF-kB, and Ets-1 [11–15].
Ets-1, a member of the Ets protein family of transcription
factors, regulates the expression of a diverse set of proteins through
its interaction with specific consensus sequences upstream of target
genes [16]. The over-expression of Ets-1 has been associated with
a multitude of different cancers, specifically with regards to tumour
progression and invasion [16–19]. Additionally, over-expression of
Ets-1 has also been associated with poor prognosis in breast [20],
ovarian [21], and cervical carcinomas [22]. Traditionally, Ets-1 is
thought to function as a transcriptional activator and its high
expression in endothelial and stromal cells correlates with tumour
cell invasiveness and unfavourable outcome in ovarian and breast
cancer [23–25]. Our laboratory and that of others have
highlighted the importance of Ets-1 in the regulation of different
aspects of cancer cell behaviour, including extracellular matrix
remodeling, invasion, angiogenesis [26], and drug resistance [27].
The link between Ets-1 and cancer invasiveness can potentially be
explained by the list of known target genes regulated by this
transcription factor. Several MMPs and integrin genes, as well as
urokinase plasminogen activator (uPA), which are all known
mediators of extracellular matrix degradation and cell migration,
are known targets for Ets-1 [28–31]. Many genes crucial to
angiogenesis and extracellular matrix remodeling, such as matrix
metalloproteinases (MMP-1, MMP-3, MMP-9), uPA and Integ-
rinb3, are under the direct regulation of Ets-1 [26]. This
transcription factor is thus considered to be an important mediator
of cancer cell development and tumour progression.
In this study we have demonstrated that Ets-1 plays a role in the
regulation of energy metabolism in ovarian cancer cells. Using
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regulates, either directly or indirectly, several important genes
involved in mitochondrial metabolic and antioxidant defense
pathways in our Ets-1 over-expression ovarian cancer cell model.
Functionally, we have shown that glycolysis, oxidative phosphor-
ylation, and cellular respiratory systems are altered in response to
changes in Ets-1 expression. Taken together, our findings indicate
that Ets-1 is a key transcription factor involved in regulating
metabolic and oxidative stress in cancer cells.
Results
Cancer cell model of Ets-1 gene expression
Ets-1 was over-expressed in 2008 ovarian cancer cells using a
tetracycline-inducible system, generating 2008-Ets1 cells. Ets-1
protein expression in tetracycline-treated 2008 and 2008-Ets1 was
examined via Western blotting (Figure 1). Ets-1 protein expression
was not detectable in 2008 whole cell lysates, but was readily
detected in the induced 2008-Ets1 lysate. Increased Ets-1
expression was found to be a specific effect as the protein levels
of two similar Ets family members, Ets-2 and PEA3 were not
altered in this model of Ets-1 over-expression (Figure 2).
Ets-1 regulates metabolic gene expression
Microarray analysis of 2008 and 2008-Ets1 cells revealed that
3,131 genes of the 28,869 genes probed were up-regulated or
down-regulated in response to Ets-1 over-expression by at least
1.45 fold (p#0.001) (GEO database accession #GSE21129). For
this study, we have chosen to report and examine changes in
selected mRNAs whose functions are relevant to mitochondrial
activity, cellular metabolism, and oxidative stress. Real time qRT-
PCR validation was conducted using 10 target genes representing
various fold change values, and results were normalized to 4
separate housekeeping genes. Although both PPARG and SDHB
gene expression in 2008-Ets1 cells were not significantly different
from 2008 cells, the fold changes determined from real time qRT-
PCR were associated with the microarray fold changes by a
correlation coefficient of 0.99 (Table 1). Therefore, fold changes
greater than 1.45 were deemed to be valid results and were
included in this study.
The expression of G6PD, PDHA, HK, and CYC were
examined by Western blotting to determine whether the gene
expression differences observed were also present at the protein
level. We did not find any significant differences in protein
expression between 2008 and 2008-Ets1 cells for any of the
enzymes examined (data not shown).
Figure 1. Generation of an ovarian cancer cell model for Ets-1
expression. 2008 ovarian cancer cells were stably transfected to over-
express Ets-1 in a tetracycline inducible system. Protein expression of
2008 and 2008-Ets1 cells was measured via Western blot following
induction with tetracycline (n=3).
doi:10.1371/journal.pone.0013565.g001
Figure 2. Ets-1 expression did not affect the expression of
similar ETS family members. The protein expression of ETS family
transcription factors (A) Ets-2 and (B) PEA3 were compared in 2008 and
2008-Ets1 ovarian cancer cells to determine the specificity of our Ets-1
expression model. Western blot analysis showed that neither of these
transcription factors was affected by Ets-1 expression in 2008 cells.
doi:10.1371/journal.pone.0013565.g002
Table 1. Real time qRT-PCR validation of microarray findings.
Gene
name
Microarray
fold change
Real time PCR
fold change Valid?
ETS1 12.70 *** 10.14 ** Y
GPX2 8.80 *** 9.95 *** Y
PPARG 2.58 *** 2.07 N
G6PD 1.74 *** 1.91 * Y
HK1 1.71 *** 2.18 ** Y
SDHB 21.30 *** 22.07 N
CYC1 21.46 *** 22.87 * Y
PDHA 22.05 *** 21.99 * Y
NDUFAB1 22.23 *** 22.76 *** Y
MMP13 211.00 *** 211.26 *** Y
Correlation Coefficient=0.99; p#0.05=*, p#0.01=**, p#0.001=***.
doi:10.1371/journal.pone.0013565.t001
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Ets-1
Microarray analysis of 2008-Ets1 ovarian cancer cells revealed
that Ets-1 is involved in the regulation of mitochondrial stress and
dysfunction as metabolic genes, including those involved in
glycolysis, glycolytic feeder pathways, the TCA cycle, and lipid
metabolism (Table 2), and genes involved in antioxidant defense
(Table 3) were altered in Ets-1 over-expressing cells. To evaluate
whether cells with stable over-expression of Ets-1 favour glycolysis
over oxidative phosphorylation for energy, as predicted by our
microarray analysis, cells were grown in glucose-free media
supplemented with the glycolytic inhibitor 2-DG, an analog of
glucose. Cells were grown in the presence of varying amounts of 2-
DG, and representative growth curves were generated for each cell
line. The growth of cells in media containing 2-DG was inhibited
to a greater extent in cells with a higher Ets-1 expression than in
parental cells (Figure 3A). The 2-DG IC50 doses, or doses where
50% of the cells had stopped proliferating, were calculated from 4
independent experiments. Our results indicated that 2008-Ets1
cells induced with tetracycline were the most sensitive to 2-DG,
with an IC50 of 0.75 mM, which was significantly lower than the
parental 2008 cells, IC50 of 4.29 mM (p#0.01). C13* cells, a
cisplatin-resistant variant of 2008 cells, had an IC50 of 2.04 mM,
which was also significantly lower than parental 2008 cells
(p#0.05). To discount any treatment effect, parental 2008 cells
were treated with tetracycline, and showed no significant growth
inhibition by 2-DG with an IC50 of 3.67 mM (data not shown).
Growth of cells in normal or glucose-free media (supplemented
with sodium pyruvate) was compared over 96 hrs, after which it
was observed that the proliferation of cells with increased
expression of Ets-1 was notably slower compared to parental
2008 cells (Figure 3B). Treatment with glucose-free media resulted
in a decreased proliferation rate for all cells tested in comparison to
normally supplemented media (data not shown).
Ets-1 regulates cellular oxygen consumption in cancer
cells
Our microarray analyses suggest that Ets-1 over-expression
resulted in an overall down-regulation of genes that encode
electron transport chain components, suggesting that these cell
lines would likely display decreased O2 consumption (Table 4).
This assumption was evaluated using high-resolution respirome-
try, where basal oxygen consumption was measured following the
addition of cells to an oxygraph. Basal oxygen consumption was
significantly lower in induced 2008-Ets1 cells (26.23 pmoles O2/
1610
6 cells/sec; p#0.05) compared to 2008 cells (40.60 pmoles
O2/1610
6 cells/sec, p#0.05) (Figure 4). No significant tetracy-
cline treatment effect on basal oxygen consumption was found
following induction of 2008 cells, confirming that tetracycline
did not affect oxygen consumption in our model (data not
shown).
Discussion
Mitochondrial reactive oxygen species activate several key
signaling pathways involved in tumourigenesis and up-regulate the
expression of important oncogenic transcription factors including
Ets-1 [32]. We have previously shown that increased production of
intracellular reactive oxygen species in C13* cells, a cisplatin-
resistant variant of 2008 ovarian carcinoma cells, correlated with
an increase in Ets-1 mRNA and protein expression [15,33].
Subsequent treatment of these cells with H2O2 increased Ets-1
Table 2. Effect of Ets-1 over-expression on glycolysis, glycolytic feeder pathways, and lipid metabolism.
Pathway Gene GenBank ID Gene name Fold change
Glycolysis Enolase 2 NM_001975 ENO2 +2.38 ***
Hexokinase1 NM_033500 HK1 +1.71 ***
Aldolase C, fructose-bisphosphate NM_005165 ALDOC +2.66 ***
Phosphoglucomutase 1 NM_002633 PGM1 +1.59 ***
Galactose UDP-galactose-4-epimerase NM_000403 GALE +1.57 ***
Galactose mutarotase (aldose 1-epimerase) NM_138801 GALM 23.54 ***
Glycogen Phosphorylase, glycogen, liver NM_002863 PYGL +2.00 ***
Citric acid cycle Citrate synthase NM_004077 CS 21.63 ***
Fumarate hydratase NM_000143 FH 21.48 ***
Pentose phosphate Glucose-6-phosphate dehydrogenase NM_000402 G6PD +1.74 ***
Phosphoglucomutase 1 NM_002633 PGM1 +1.59 ***
Transketolase NM_001135055 TKT +2.07 ***
Lipid metabolism Apolipoprotein B mRNA editing catalytic polypeptide-like 3G NM_021822 APOBEC3G +2.25 ***
Fatty acid desaturase 1 NM_013402 FADS1 +6.47 ***
Fatty acid desaturase 2 NM_004265 FADS2 +5.29 ***
Fatty acid synthase NM_004104 FASN +1.61 ***
Lysophosphatidylcholine acyltransferase 2 NM_017839 LPCAT2 +2.56 ***
Phospholipase C, beta 3 NM_000932 PLCB3 +2.75 ***
Prostaglandin-endoperoxide synthase 1 NM_000962 PTGS1 +3.88 ***
Protein kinase, AMP-activated, beta 2 NM_005399 PRKAB2 +2.05 ***
p#0.05=*, p#0.01=**, p#0.001=***.
doi:10.1371/journal.pone.0013565.t002
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transcription factor is highly responsive to tumour-derived signals.
Our previous analysis of the Ets-1 promoter led to the
identification of an antioxidant response element (ARE) that
proved to be pivotal in regulating the expression of Ets-1 under
both basal and H2O2-induced conditions [15]. Traditionally, the
functional importance of Ets-1 over-expression in cancer has been
associated with the regulation of matrix-degrading proteases and
angiogenic factors [26,34]. However, our recent findings that
mitochondrial reactive oxygen species potently affects Ets-1
expression at the transcriptional level [15] suggest that the
importance of this transcription factor in cancer initiation and
progression extends beyond angiogenesis and metastasis alone.
We hypothesized that Ets-1 may be involved in the regulation of
mitochondrial metabolism in cancer cells because mitochondrial
stress from both increased reactive oxygen species production and
electron transport chain malfunction result in increased Ets-1
mRNA and protein [15]. In order to determine the functional
importance of Ets-1 expression in cancer cell metabolism, we
generated the tetracycline-inducible Ets-1 over-expressing ovarian
cancer cell line 2008-Ets1. Parental 2008 cells do not express
detectable levels of Ets-1 protein endogenously. To analyze the
genomic consequences of Ets-1 over-expression in these ovarian
cancer cells, we conducted a human gene microarray. Our
findings indicate that Ets-1 is either directly or indirectly involved
in regulating the expression of more than 3,000 of the over 28,000
human genes examined. Interestingly, our findings suggest that
Ets-1 could act as a transcriptional repressor of more than half
(1,665) of these genes in ovarian carcinoma cells.
Although Ets-1 has been studied extensively in both physiolog-
ical and pathological processes [17], it is rarely referred to as a
transcriptional repressor. In the context of mitochondrial dysfunc-
tion and metabolism, Ets-1 was found to at least partially down-
regulate several components of the electron transport chain.
Complex I, the most prominent site for electron leakage leading to
excessive reactive oxygen species production in the electron
transport chain, is composed of 39 nuclear encoded subunit genes,
of which Ets-1 down-regulates 11. Another important site for
electron leakage and reactive oxygen species production is
Complex III, which is composed of 10 subunits, of which Ets-1
down-regulates 3. Ets-1 also represses components of Complex IV,
Complex V ATP synthases, as well as some electron transport
associated factors. Taken together, these repressive functions
suggest that Ets-1 is prominently involved in the decreased reliance
on oxidative phosphorylation frequently associated with cancer
cells. Consequently, genes encoding mitochondrial proteins
involved in oxidative phosphorylation would be down-regulated,
and cells would require alternate methods of ATP production
including glycolysis and fatty acid oxidation. Given that compo-
nents of almost every complex of the electron transport chain,
several key enzymes of the TCA cycle, and ultimately the reducing
equivalents needed for electron transport were similarly down-
regulated, Ets-1 over-expressing cells appear to have a decreased
capacity to generate ATP via oxidative phosphorylation at the
gene expression level.
Cancer cells commonly have a decreased reliance on oxidative
phosphorylation for energy generation, and they likewise have an
increased dependence on glycolysis and fat metabolism for cellular
energy [35]. In further support that Ets-1 is involved in the
regulation of altered cancer metabolism, Ets-1 is associated with
the increased expression of many genes involved in glycolysis,
glycolytic feeder pathways, and the pentose phosphate pathway.
Additionally, the expression of Ets-1 is also correlated with
increases in the expression of many genes involved with lipid
metabolism and biosynthesis. Taken together, these trends suggest
that Ets-1 is an important transcriptional regulator not only in the
catabolic, but also anabolic metabolic transitions of cancer cells
that ultimately promote tumourigenesis [35].
It was almost half a century ago when the up-regulation of fatty
acid synthase (FASN) was first described in cancer [36], which is
now known to be over-expressed in the majority of cancers.
Interestingly, Ets-1 was also found to be involved in the regulation
of increased FASN gene expression in our ovarian cancer model.
Thus, our gene expression findings suggest that Ets-1 is a key
transcription factor involved in the metabolism of cancer cells, and
particularly important in the metabolic shift towards glycolysis and
Table 3. Effect of Ets-1 over-expression in oxidative stress.
Pathway Gene GenBank ID Gene name Fold change
Antioxidant defense Glutathione peroxidase 1 NM_000581.2 GPX1 +1.98 ***
Glutathione peroxidase 2 NM_005333 GPX2 +8.81 ***
Glutathione peroxidase 3 NM_002084 GPX3 +4.19 ***
Peroxiredoxin 5 NM_012094 PRDX5 +1.54 ***
ROS metabolism Arachidonate 12-lipoxygenase NM_000697 ALOX12 21.81 **
GTF2I repeat domain containing 2 NM_173537 GTF2IRD2 +1.92 ***
GTF2I repeat domain containing 2B NM_001003795 GTF2IRD2B +2.19 ***
Neutrophil cytosolic factor 2 NM_000433 NCF2 22.24 ***
Superoxide dismutase 2 (mitochondrial) NM_001024465 SOD2 21.49 ***
ATX1 antioxidant protein 1 NM_004045 ATOX1 +1.53 ***
Prion protein NM_000311 PRNP 21.60 ***
Scavenger receptor class A, member 3 NM_016240 SCARA3 +1.48 **
Selenoprotein P, plasma, 1 NM_005410 SEPP1 22.04 ***
Aldehyde oxidase 1 NM_001159 AOX1 +2.81 ***
BCL2/adenovirus E1B interacting protein 3 NM_004052 BNIP3 +3.15 ***
p#0.05=*, p#0.01=**, p#0.001=***.
doi:10.1371/journal.pone.0013565.t003
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note that Ets-1-mediated metabolic regulation is likely achieved by
a large consortium of different transcription factors, a more
complex regulatory network of transcription factors influenced by
mitochondrial dysfunction have yet to be elucidated. We have
demonstrated that the over-expression of Ets-1 in our ovarian
cancer model did not affect protein levels of two closely related
ETS family members; however, it is possible that other ETS
transcription factors from this very large family also influence
cancer metabolism. Considering that these transcription factors
recognize almost identical consensus sequences, the repetition of
the experiments within this study following the over-expression of
other ETS family members could yield similar results. In addition,
such experiments would further characterize the potentially large
transcriptional network involved in the specialized metabolism of
cancer cells.
To determine the functional relevance of our genomic results,
we have examined the glycolytic capability of our Ets-1 over-
expression model. We have indirectly evaluated the oxidative
phosphorylation capacity of these cells through treatment with the
glycolytic inhibitor 2-DG. Ovarian C13* and induced 2008-Ets1
cells, which both express Ets-1, showed prominent growth
inhibition in response to 2-DG, suggesting that these cells are
more reliant on glycolysis for ATP production. Additionally, the
Ets-1 over-expressing ovarian cancer cells displayed significantly
decreased growth following glucose deprivation, further empha-
sizing their glycolytic reliance. The growth rate of all cell types in
glucose-free media was decreased as compared to normally
supplemented media, particularly after 48 hrs when a distinct
divergence in cell growth was consistently observed, likely due to
decreased glucose availability. Over-expression of Ets-1 potently
exacerbated this divergence as the growth of induced 2008-Ets1
cells drastically decreased after 48 hrs. However at the protein
level, we did not find any significant differences in the expression
of glucose-6-phosphate dehydrogenase, pyruvate dehydrogenase,
cytochrome c, or hexokinase, which are all enzymes involved in
glycolysis or oxidative phosphorylation. Importantly, we did see
repeatable and significant differences in glycolytic dependence
associated with Ets-1 expression, and the lack of changes in protein
expression could therefore be due to post-translational modifica-
tions mediated by Ets-1. For example, differences within the
catalytic region of an enzyme would result in functional
differences, but would not necessarily be detectable via Western
blot, as this technique is dependent on the specific epitope targeted
by the antibody used. Thus, we plan to examine the enzyme
activity of these metabolic enzymes in future studies to determine if
any differences exist between 2008 and 2008-Ets1 cells that could
account for the functional differences we have demonstrated in
this study.
The evaluation of O2 consumption of a population of cells is a
functional evaluation of oxidative capacity, as it represents a good
estimate of the rate at which electrons are passing along the
electron transport chain and being reduced to H2O2. The
polarographic system used in this study to measure O2
consumption includes sensors that yield a current proportional
to the partial pressure of O2 in cell containing media by
consuming O2 in a cathode half reaction, thus the signal responds
exponentially to changes in O2 pressure within the sample. In the
absence of specific complex substrates and ADP, thereby
simulating respiration, the basal rate of O2 consumption can be
measured. We have observed significant decreases in O2
consumption in cells with increased Ets-1 expression. Our results
indicate that Ets-1 is directly involved in the regulation of cellular
oxidative capacity, where Ets-1 over-expression led to significantly
decreased O2 consumption, and Ets-1 down-regulated cells
displayed a very prominent increase in O2 consumption. These
results suggest that up-regulated Ets-1 expression promotes a
decreased dependence on oxidative phosphorylation for energy,
and provides further evidence towards the functional importance
of Ets-1 in cancer cell metabolism.
High levels of oxidative stress are typically observed in the
tumour microenvironment as a result of imbalances in antioxidant
defense factors, and impaired DNA repair mechanisms [37–39].
In breast cancer cells lines, increased malignancy is associated with
high levels of reactive oxygen species-producing superoxide
dismutase activity, in combination with decreased levels of reactive
oxygen species-detoxifying glutathione peroxidases and the H2O2-
detoxifying enzyme catalase [40]. Similar antioxidant enzyme
imbalances have been found in melanoma [41], as well as lung
[42], prostate [43], and thyroid cancers [44]. Our microarray
analysis determined that Ets-1 is a regulator of antioxidant gene
expression in ovarian cancer cells, particularly glutathione
peroxidases, which preferentially target H2O2 and lipid hydro-
peroxides for detoxification. This increased expression of antiox-
idants is in response to mitochondrial oxidative stress in the form
of excessive reactive oxygen species production, and we have
previously shown that Ets-1 gene expression increases in response
Figure 3. Glycolytic dependence of Ets-1-expressing ovarian
cancer cells. (A) 2008, C13*, and 2008-Ets1 cells were treated with the
glycolytic inhibitor 2-DG, and cellular growth was measured following
96 hours of incubation. 2008-Ets1 and C13* cells which express Ets-1
showed significantly decreased growth following glycolytic inhibition in
2008-Ets1 compared to parental 2008 cells (n=4). (B) 2008 and 2008-
Ets1 cells were grown in the absence of glucose, and proliferation
assays were conducted at 24 hour intervals. 2008-Ets1 ovarian cancer
cells expressing high levels of Ets-1 showed a decreased ability for
growth in glucose-free culture medium, suggesting an increased
reliance on glycolysis for energy (n=3).
doi:10.1371/journal.pone.0013565.g003
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down-regulated genes encoding certain H2O2-detoxifying en-
zymes, suggesting that these cancer cells likely require and
maintain a certain level of H2O2 to encourage the high growth
rates inherent to tumour progression.
A novel function for Ets-1 was elucidated in this study following
genomic and functional analysis of an ovarian cancer Ets-1
expression model. To our knowledge, this is the first study to show
a role for this transcription factor in metabolism. Numerous down-
regulated genes were identified in Ets-1 over-expressing cells
including those encoding several mitochondrial proteins involved
in oxidative phosphorylation, as well as important metabolic
enzymes that are responsible for the generation of required
substrates of the electron transport chain. Functional assays
confirmed that Ets-1 over-expressing cancer cells displayed
reduced oxidative phosphorylation capabilities, as well as en-
hanced reliance on glycolysis for cellular energy. Additionally, Ets-
1 was shown to be important in the regulation of cellular O2
consumption further suggesting a reduced usage of oxidative
phosphorylation in cancer cells expressing Ets-1.
Therefore, damage to the mitochondria results in increased
production of H2O2 and consequent up-regulation of Ets-1, which
then participates in an active regulatory network that encourages
reliance on glycolysis and lipid metabolism for cellular energy
requirements. Thus, Ets-1 may be grouped with other transcrip-
tion factors that have been observed to up-regulate the expression
of mitochondrial proteins (NRFs) or genes involved in glycolysis
(HIF-1) in response to specific stresses [45,46]. In summary, our
findings demonstrate a novel role for Ets-1 in the regulation of
cellular metabolism in response to mitochondrial stress.
Materials and Methods
Cell culture
The human ovarian carcinoma cell lines, 2008 and C13*, were
kindly provided by Dr. Paul Andrews (Georgetown University,
Rockville MD) [33]. The 2008 and C13* cells were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum
and 2% penicillin/streptomycin. The stable cell line 2008-Ets1
[27] was maintained in growth medium as described with the
addition of 200 ng/ml of the selective antibiotic Zeocin. All cells
were kept at 37uC in a humidified atmosphere of 5% CO2. Media
and supplements were purchased from Invitrogen Life Technol-
ogies (Burlington, ON, Canada), and FBS from Fisher Scientific
(Ottawa, ON, Canada). All reagents were purchased from Sigma
(Oakville, ON, Canada).
Protein isolation and Western blot analysis
Whole cell lysates were collected, 30 mg of protein were
separated by 10% SDS-PAGE electrophoresis, transferred to
nitrocellulose membrane (Amersham Biosciences, Baie D’Urfe,
Table 4. Effect of Ets-1 over-expression on the ETC.
Component Gene GenBank ID Gene name Fold change
Complex I NADH dehydrogenase (ubiquinone) 1 a subcomplex 1 NM_004541 NDUFA1 21.60 ***
NADH dehydrogenase (ubiquinone) 1 a subcomplex 9 NM_005002 NDUFA9 21.59 ***
NADH dehydrogenase (ubiquinone) 1, a/b subcomplex 1 NM_005003 NDUFAB1 22.23 ***
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 NM_002492 NDUFB5 21.50 ***
NADH dehydrogenase (ubiquinone) 1 b subcomplex 11 NR_024234 NDUFB11 21.48 ***
NADH dehydrogenase (ubiquinone) 1 a subcomplex assembly factor 1 NM_016013 NDUFAF1 21.71 ***
NADH dehydrogenase (ubiquinone) Fe-S protein 4 NM_002495 NDUFS4 21.58 ***
Complex III Cytochrome c-1 NM_001916 CYC1 21.46 ***
Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 NM_006003 UQCRFS1 21.50 ***
Ubiquinol-cytochrome c reductase, complex III subunit VII NM_014402 UQCRQ 21.50 ***
Complex IV Cytochrome c oxidase subunit 7b NM_001866 COX7B 22.08 ***
ATP Synthases ATP synthase, H+ transporting, mitochondrial F1 complex, a subunit 1, cardiac muscle NM_001001937 ATP5A1 21.53 ***
ATPase, H+ transporting, lysosomal accessory protein 2 NM_005765 ATP6AP2 21.50 ***
Electron transport
associated factors
Cytochrome c, somatic NM_018947 CYCS 21.51 ***
Holocytochrome c synthase (cytochrome c heme-lyase) NM_005333 HCCS 21.76 ***
p#0.05=*, p#0.01=**, p#0.001=***.
doi:10.1371/journal.pone.0013565.t004
Figure 4. Effect of Ets-1 expression on oxygen consumption.
Basal oxygen consumption was determined for 2008 and 2008-Ets1
ovarian cancer cells. Ets-1 expression was associated with a significant
decrease in basal oxygen consumption suggesting a decreased reliance
on oxidative phosphorylation in 2008-Ets1 cells.
doi:10.1371/journal.pone.0013565.g004
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Membranes were incubated overnight with primary antibody in
0.5% skim milk TBS-T. Following primary antibody incubation,
membranes were washed and incubated for 1 hr with horseradish
peroxidase-linked IgG secondary antibody (1:10,000) (Santa Cruz
Biotechnology Inc., Santa Cruz, CA). Proteins were detected using
ECL chemiluminescence reagent (Amersham), and exposed to
film. Antibodies against Ets-1 (1:100), G6PD (1:1000), and PDHA
(1:500) were from Abcam; antibodies against Ets-2 (1:500), PEA3
(1:100), and HK (1:250) were from Santa Cruz Biotechnology; and
the antibody against CYC (1:250) was from BD Biosciences.
RNA isolation and quantitative real-time PCR
Total RNA was isolated using Trizol reagent as indicated by the
manufacturer (Invitrogen). RNA samples were DNase treated
using Turbo DNA-free
TM as per the manufacturer’s directions
(Ambion), and 3 ug of total cellular RNA was reverse-transcribed
using poly-T primers and the Superscript III First Strand Synthesis
System (Invitrogen). Quantitative real-time PCR was conducted
using a DNA EngineH thermal cycler (Bio-Rad) and Platinum
SYBR Green qPCR SuperMix UDG (Invitrogen) with primer
sequences listed in Table 5. Target gene expression was
normalized to the pooled gene expression values of b-actin
(ACTB), B-2 macroglobulin (B2M), glyceraldehyde-3-phosphdate
dehydrogenate (GAPDH), and RNA polymerase II (RPII) as
housekeeping controls. Data was normalized to housekeeper gene
expression and efficiency corrected using the DDCt method of
relative quantification, where statistical significance and standard
error were determined from DCt values.
Microarray analysis
Total RNA was isolated from tetracycline-induced 2008 and
2008-Ets1 cells as described, purified using the RNeasy purifica-
tion kit (Qiagen), and hybridized to the GeneChipH Human Gene
1.0 ST Array (28,869 human gene probes). RNA quality analysis
via bioanalyzer, microarray preparation, hybridization, and
detection were performed by The Centre for Applied Genomics,
The Hospital for Sick Children, Toronto, Canada. All low-level
analyses, calculationof differential expression, and statistical adjust-
ments were computed using R version 2.9.2 [47]. Assessment of
RNA quality post-hybridization, and low-level analysis were
performed using the package ‘affy’ [48]. RNA degradation plots
revealed little 59 to 39 bias and all arrays were within 1.35 standard
deviations of the average slope. Background correction and
normalization was performed using the robust multi-array average
(RMA) algorithm. To reduce the number of differential expression
tests downstream, thereby increasing overall power, 50% of the
lowest normalized Log2 probe-set intensities were removed
according to recommendations by Hackstadt and Hess (2009)
[49]. Differential expression estimates were computed using the
adjusted Local Pooled Error test in the package ‘LPEadj’ [50]. The
Benjamini-Hochberg procedure for controlling false discovery rate
(FDR) was applied to comparison-wise p-values using the package
‘multtest’. Reported q-values represent the minimum FDR at
which a particular test can be considered significant. Fold change
expression values of 10 random target genes of varying fold change
magnitude were validated using real time PCR. Corresponding
relative fold changes were determined using the DDCT method of
relative quantification, and correlation coefficients were calculated
to determine the relationship between real time PCR and
microarray findings.
Glycolytic dependency assays
Cellular growth rate and the inhibition of proliferation were
evaluated by assessing total cell numbers, where 2610
3 cells were
plated onto 96-well tissue culture plates and allowed to adhere.
Cells were treated with 2-deoxy-D-glucose (2-DG; Sigma)
administered at concentrations ranging from 1–7.5 mM over
96 hrs, at which time a Hoechst DNA content assay (Invitrogen)
was performed. Following treatment, cells were washed and lysed
in MilliQ water and 2 mg/mL Hoechst 33258 stain diluted in
TNE buffer (10 mM Tris, 1 mM EDTA, 2 M NaCl, pH 7.4).
Fluorescence was evaluated using a Cytofluor series 4000 multi-
well plate reader (excitation 350 nm, emission 460 nm) (PerSep-
tive Biosystems, Framingham, MA). Cell number was standard-
ized to fluorescence for each cell type by comparison with a
standard curve of known cell numbers. To determine cell growth
in glucose free media, glucose free RPMI and DMEM media
supplemented with 110 mg/L pyruvate was added to cells
following overnight adherence. Plates of cells were frozen every
Table 5. Primer sequences used for real time qRT-PCR.
Gene name (acronym) Forward primer (59-39) Reverse primer (59-39)
b-actin (ACTB) cctccctggagaagagctac gatgtccacgtcacacttca
B-2 macroglobulin (B2M) gctatccagcgtactccaaag tcacacggcaggcatactc
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) atcatcagcaatgcctcctg ctgcttcaccaccttcttga
RNA polymerase II (RPII) gaaacggtggacgtgcttat tctccatgccatacttgcac
Cytochrome c 1 (CYC1) ccaatgaagatccccacatg ccaggaaagtaggggttgaagt
V-ets erythroblastosis virus E26 oncogene homolog 1 (ETS1) tgtattttgcatccctggtt aacgacatcgattcaggact
Glucose-6-phosphate dehydrogenase (G6PD) tggaaccgggacaacatc caacaccttgaccttctcatcac
Glutathione peroxidase 2 (GPX2) cccctacccttatgatgacc gttgatggttgggaaggtg
Hexokinase 1 (HK1) ggcgtttccacaagactcta cttggtgaggtggaaatgag
Matrix metallopeptidase 13 (MMP13) cagtctttcttcggcttagagg cagaggagttacatcggacca
NADH dehydrogenase 1, a/b subcomplex 1 (NDUFAB1) cgtctcgtcgtcctttcagc cctggatgccctctaacg
Pyruvate dehydrogenase a 1 (PDHA) cacagaccatctcatcacagt ggcagacctcatcttttcca
Peroxisome proliferator-activated receptor c (PPARG) cctattgacccagaaagcgatt cattacggagagatccacgga
Succinate dehydrogenase complex, subunit B (SDHB) atcttgttcccgatttgagc gtctccgttccaccagtacg
doi:10.1371/journal.pone.0013565.t005
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assays were performed at each time point.
Oxygen consumption assay
All oxygen consumption assays were performed on the
OROBOROS oxygraph (Oroboros, Innsbruck, Austria) at 37uC.
Cells were pelleted, resuspended in growth medium, and 3610
6
cells were used per experiment at a density of 1610
6 cells/100 mL.
Freshly harvested cells were added to the oxygraph chambers
containing 1.8 mL of KCl medium (80 mM KCl, 10 mM Tris-
HCl, 3 mM MgCl2, 1 mM EDTA, 5 mM potassium phosphate,
pH 7.2). The total O2 concentration and flux were recorded at
1 sec intervals throughout the experiment. Once the oxygen
concentration stabilized, the basal O2 consumption was deter-
mined for each cell line and condition, where OROBOROS
software was used for data acquisition and analysis.
Statistical analysis
Data is presented as the mean +/2 standard deviation from at
least three independent experiments. Statistically significant
differences between sample groups were determined using a
Student’s t-test or ANOVA where applicable, with a p-value#0.05
considered to be statistically significant (p#0.05=*, p#0.01=**,
p#0.001=***).
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